Answers are grounded in this paper and cite their sources.
Acute kidney injury (AKI) represents a critical clinical condition marked by abrupt deterioration of renal function, primarily driven by oxidative stress, inflammation, and apoptosis. However, effective targeted therapies remain limited. Here, a smart, biomimetic nanoplatform (CeAst@MK) that synergistically addresses oxidative and inflammatory injury in AKI is reported. CeAst nanoparticles are formed via coordination between Ce 3 ⁺ ions and astragalin (Ast), a natural flavonoid with intrinsic ROS‐scavenging and anti‐inflammatory properties. To enhance immune evasion and renal targeting specificity, CeAst is cloaked with macrophage membranes (MCM) and modified with a kidney‐targeting peptide (KTP), yielding the final CeAst@MK system. The platform exhibits pH‐responsive release in the acidic microenvironment of injured renal tissues, enabling precise and rapid therapeutic delivery. In both LPS‐ and ischemia reperfusion‐induced AKI models, CeAst@MK significantly improves renal function, suppresses proinflammatory cytokines, and promotes M2 macrophage polarization. Mechanistically, it modulates PI3K/Akt and NF‐κB pathways, achieving dual antioxidative and anti‐inflammatory effects. This study presents a translationally promising nanotherapeutic system integrating natural antioxidants, biomimetic camouflage, and tissue‐specific delivery, offering an effective and precise strategy for AKI intervention.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: